CIA
BMRN icon

Choate Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Choate Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,292
Closed -$794K – 328
2022
Q1 		$794K Buy
+10,292
New +$861K 0.04% 164

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Choate Investment Advisors's BMRN Position: Q2 2022 in Review

Choate Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 10,292 shares — an estimated $794K sold.

Choate Investment Advisors first reported a position in BMRN in Q1 2022 and held it in 1 quarter. The position peaked at $794K in Q1 2022. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

  • Choate Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Choate Investment Advisors sold 10,292 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $794K.
  • Choate Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Choate Investment Advisors's BioMarin Pharmaceuticals position peaked at $794K in Q1 2022.
  • 542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Choate Investment Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.